Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC

Clinical trial NCT01755923 · UNKNOWN

Trial details

NCT number: NCT01755923
Sponsor: Peking Union Medical College Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer

Start date: 2012-12-01
Primary completion: 2013-12-01
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.